Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-11-21
1998-11-24
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
4241301, 4241411, 4241431, 4241441, 4241531, 4241541, 4241731, 435 71, 435 72, 435 721, 435 724, 435 696, 4351723, 4352513, 4353201, 5303873, 53038873, 53038875, 53038822, 536 2353, A61K 39395, C07K 1628, C12P 2108, C12N 1513
Patent
active
058402993
ABSTRACT:
The invention provides humanized immunoglobulins that specifically bind to the VLA-4 ligand, and methods of treatment using the same. The methods are particularly useful for treatment of multiple sclerosis.
REFERENCES:
patent: 5260210 (1993-11-01), Rubin et al.
patent: 5530101 (1996-06-01), Queen et al.
Lisak et al. J. Neurol. Sciences 62: 281-293 (1983).
Teitelbaum et al. PNAS 89: 137-141 (1992).
Weiner et al. Science 259: 1321-1324 (1993).
Racke et al. J. Neuroimmunol. 46: 175-184 (1993).
Karussis et al PNAS 90: 6400-6404 (1993).
Cannella et al. Ann Neurol. 37: 424-435 (1995).
Washington et al. Ann Neurol 35: 89-97 (1994).
Dore-Duffy et al. in Frontiers in Cerebral Vascular Biology: Transport and its Regulation (eds) Dreues and Betz Plenum Press Ny 1993 pp. 243-248.
Monshizadegan et al., "VLA-4-dependent adhesion activities of U937 cells and guinea peg bronchoalveolar lavage leukocytes", 1993, Agents Actions 39, pp. C177-C179.
Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting the importance of framework residues on loop conformation", 1991, Protein Engineering, vol. 4, No. 7, pp. 773-783.
Yednock et al. "Prevention of experimental autoimmune encephalomyelitis by antibodies against .alpha.4.beta.1 integrin", 1991, Letters to Nature, vol. 356, pp. 63-66.
W. J. Harris and S. Emery, "Therapeutic antibodies--the coming of age", 1993, Tibtech, vol. 11, pp. 42-45.
S. C. Emery and J. R. Adair, "Humanised monoclonal antibodies for therapeutic applications", 1994, Exp. Opin. Invest. Drugs, vol. 3, pp. 241-251.
S. M. Edgington, "How Sweet It Is: Selectin-Mediating Drugs", 1992, Bio/Technology, vol. 10, pp. 383-389.
Elices et al., "VCAM-1 on Activated Endothelium Interacts with the Leukocyte Integrin VLA-4 at a Site Distinct form the VLA-4/Fibronectin Binding Site", 1990, Cell, vol. 60, pp. 577-584.
Dijkstra et al., "Multiple sclerosis: some possible therapeutic opportunities", 1993, Tips Reviews, vol. 14, pp. 124-129.
A. Mountain and J.R. Adair, "Engineering Antibodies for Therapy", 1992, Biotech Genetic Engineering Reviews, vol. 10, pp. 10-13.
P.A. Ward and M.S. Mulligan, "Blocking of adhesion molecules in vivo as anti-inflammatory therapy", 1994, Therapeutic Immunol, vol. 10, pp. 165-171.
L. K. Jolliffe, "Humanized Antibodies: Enhancing Therapeutic Utility Through Antibody Engineering", 1993, Intern Rev Immunol, vol. 10, pp. 241-250.
Albelda Faseb J. 8: 504-512 (1994).
Kahan Curr Opin Immunology 4: 553-560 (1992).
Natanson et al. Ann Intern Med. 120: 771-783 (1994).
Dalakas Ann. Neurol. 37(51): 52-513 (1995).
Paul (ed) Fundamental Immunology Raven Press NY 1993 p. 242 only.
Bendig Mary M.
Jones S. Tarran
Leger Olivier J.
Saldanha Jose
Yednock Ted A.
Athena Neurosciences, Inc.
Feisee Lila
Gambel Phillip
LandOfFree
Humanized antibodies against leukocyte adhesion molecule VLA-4 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized antibodies against leukocyte adhesion molecule VLA-4, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized antibodies against leukocyte adhesion molecule VLA-4 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1699161